$8.8 M

ABIO Mkt cap, 18-Oct-2018
ARCA biopharma Net income (Q2, 2018)-4.9 M
ARCA biopharma EBIT (Q2, 2018)-4.9 M
ARCA biopharma Cash, 30-Jun-20189.6 M

ARCA biopharma Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

14.1m

General and administrative expense

4.6m

Operating expense total

18.7m

EBIT

(18.7m)

Interest expense

6.0k

Interest income

167.0k

Pre tax profit

(18.6m)

Income tax expense

61.0k

Net Income

(16.4m)(18.5m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

R&D expense

1.4m1.3m1.7m2.9m

General and administrative expense

1.0m950.0k1.1m2.1m

Operating expense total

2.4m2.3m2.8m4.9m

EBIT

(2.4m)(2.3m)(2.8m)(4.9m)

Interest expense

3.0k6.0k

Interest income

41.0k84.0k

Pre tax profit

(2.4m)(2.3m)

Net Income

(4.8m)(7.1m)(2.7m)(5.5m)(8.3m)(3.6m)(7.5m)(12.2m)(4.3m)(2.7m)(4.9m)

ARCA biopharma Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

7.4m8.7m

Current Assets

21.4m12.3m

PP&E

66.0k42.0k

Total Assets

24.6m12.4m

Accounts Payable

1.2m622.0k

Current Liabilities

2.4m2.1m

Total Liabilities

2.4m2.1m

Additional Paid-in Capital

134.7m141.3m

Retained Earnings

(112.5m)(131.0m)

Total Equity

22.2m10.3m

Financial Leverage

1.1 x1.2 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Cash

19.4m17.2m12.2m44.1m41.5m29.7m14.4m8.1m6.2m12.1m9.6m

Current Assets

19.7m17.5m12.7m44.3m41.7m31.0m26.7m23.8m19.9m12.7m10.0m

PP&E

29.0k26.0k34.0k34.0k31.0k24.0k76.0k69.0k59.0k37.0k33.0k

Total Assets

20.5m18.0m13.3m45.1m42.4m36.9m32.6m28.7m20.6m12.8m10.1m

Accounts Payable

725.0k365.0k651.0k714.0k647.0k744.0k760.0k1.1m980.0k772.0k406.0k

Current Liabilities

1.2m838.0k1.1m1.4m1.3m2.3m1.7m2.2m2.5m1.7m1.1m

Total Liabilities

1.7m1.1m

Additional Paid-in Capital

99.0m99.2m99.5m133.8m134.0m134.3m134.5m134.7m134.9m144.8m144.8m

Retained Earnings

(79.7m)(82.0m)(87.4m)(90.1m)(92.9m)(99.7m)(103.6m)(108.3m)(116.8m)(133.7m)(135.9m)

Total Equity

43.8m41.1m34.6m30.9m26.5m18.0m11.1m9.0m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.1 x

ARCA biopharma Cash Flow

Annual

USDFY, 2016FY, 2017

Net Income

(16.4m)(18.5m)

Depreciation and Amortization

24.0k27.0k

Accounts Payable

841.0k(583.0k)

Cash From Operating Activities

(15.0m)(17.5m)

Purchases of PP&E

(12.0k)(3.0k)

Cash From Investing Activities

(16.4m)12.9m

Cash From Financing Activities

34.0m5.8m

Interest Paid

4.0k6.0k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.8m)(7.1m)(2.7m)(5.5m)(8.3m)(3.6m)(7.5m)(12.2m)(4.3m)(2.7m)(4.9m)

Depreciation and Amortization

5.0k8.0k4.0k9.0k14.0k5.0k9.0k17.0k7.0k6.0k11.0k

Accounts Payable

128.0k(232.0k)(144.0k)(198.0k)(167.0k)380.0k391.0k648.0k(234.0k)(14.0k)(217.0k)

Cash From Operating Activities

(5.4m)(7.5m)(3.1m)(5.5m)(7.9m)(3.9m)(7.4m)(11.1m)(4.3m)(3.1m)(5.3m)

Purchases of PP&E

(5.0k)(5.0k)(2.0k)(7.0k)(9.0k)(1.0k)(2.0k)(8.0k)(1.0k)(1.0k)(1.0k)

Cash From Investing Activities

(5.0k)(5.0k)(2.0k)(7.0k)(9.0k)(5.2m)(17.0m)(19.6m)3.0m3.0m3.0m

Cash From Financing Activities

8.1m8.0m(55.0k)34.3m34.1m(55.0k)34.3m34.1m105.0k3.4m3.2m

Interest Paid

2.0k3.0k1.0k3.0k4.0k1.0k3.0k4.0k6.0k

ARCA biopharma Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information